X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2263) 2263
Publication (276) 276
Book Review (17) 17
Book Chapter (13) 13
Conference Proceeding (5) 5
Dissertation (5) 5
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rolipram (1585) 1585
animals (1428) 1428
phosphodiesterase inhibitors - pharmacology (866) 866
male (859) 859
humans (739) 739
rats (706) 706
rolipram - pharmacology (643) 643
pharmacology & pharmacy (616) 616
index medicus (544) 544
pyrrolidinones - pharmacology (523) 523
cyclic amp - metabolism (487) 487
cyclic nucleotide phosphodiesterases, type 4 (446) 446
mice (433) 433
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (378) 378
phosphodiesterase (367) 367
neurosciences (358) 358
camp (341) 341
female (322) 322
dose-response relationship, drug (291) 291
biochemistry & molecular biology (288) 288
3',5'-cyclic-amp phosphodiesterases - metabolism (274) 274
rats, sprague-dawley (232) 232
in vitro techniques (227) 227
expression (225) 225
cyclic amp (223) 223
colforsin - pharmacology (177) 177
phosphodiesterase inhibitors (176) 176
cells, cultured (171) 171
asthma (166) 166
brain (164) 164
cell biology (164) 164
cyclic-amp (164) 164
disease models, animal (161) 161
rats, wistar (160) 160
guinea pigs (157) 157
phosphorylation (157) 157
inhibitors (153) 153
inflammation (151) 151
phosphodiesterase inhibitors - therapeutic use (151) 151
cyclic nucleotide phosphodiesterases, type 4 - metabolism (149) 149
cells (140) 140
phosphodiesterase 4 inhibitors - pharmacology (140) 140
activation (137) 137
kinetics (125) 125
phosphoric diester hydrolases - metabolism (125) 125
cyclic-nucleotide phosphodiesterase (122) 122
pde4 (121) 121
cyclic-nucleotide phosphodiesterases (119) 119
time factors (117) 117
3',5'-cyclic-amp phosphodiesterases - genetics (116) 116
analysis (115) 115
rolipram - therapeutic use (115) 115
isoenzymes - metabolism (113) 113
rat (113) 113
immunology (112) 112
camp-specific phosphodiesterase (111) 111
cell line (110) 110
mice, inbred c57bl (110) 110
enzyme inhibitors - pharmacology (109) 109
memory (109) 109
1-methyl-3-isobutylxanthine - pharmacology (106) 106
chemistry, medicinal (106) 106
phosphodiesterase inhibitor (106) 106
cyclic amp-dependent protein kinases - metabolism (105) 105
tumor-necrosis-factor (105) 105
in-vitro (104) 104
article (102) 102
isoenzymes - antagonists & inhibitors (102) 102
signal transduction (98) 98
inhibition (97) 97
purinones - pharmacology (92) 92
phosphodiesterase 4 inhibitors (91) 91
signal transduction - drug effects (91) 91
molecular sequence data (90) 90
phosphodiesterases (89) 89
physiology (89) 89
proteins (88) 88
long-term potentiation (86) 86
cyclic nucleotide phosphodiesterases, type 3 (85) 85
isoproterenol - pharmacology (85) 85
respiratory system (85) 85
protein-kinase (84) 84
rodents (83) 83
tnf-alpha (83) 83
adult (82) 82
binding (82) 82
rat-brain (82) 82
structure-activity relationship (81) 81
psychiatry (80) 80
research article (80) 80
identification (79) 79
tumor necrosis factor-alpha - metabolism (77) 77
cyclic amp - physiology (76) 76
forskolin (76) 76
chemistry, organic (75) 75
hippocampus (75) 75
pyridines - pharmacology (75) 75
cyclic gmp - metabolism (74) 74
research (74) 74
amino acid sequence (73) 73
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2255) 2255
Japanese (26) 26
German (8) 8
French (6) 6
Chinese (5) 5
Korean (2) 2
Polish (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Imaging and Biology, ISSN 1536-1632, 8/2018, Volume 20, Issue 4, pp. 615 - 622
Phosphodiesterase 4 (PDE4) inhibition in the brain has been reported to improve cognitive function in animal models. Therefore, PDE4 inhibitors are one of key... 
Primate | Roflumilast | Medicine & Public Health | Imaging / Radiology | PDE4 | PET | RODENTS | PHOSPHODIESTERASE-4 INHIBITOR | QUANTIFICATION | PERFORMANCE | IMPROVES MEMORY | ROLIPRAM | OBSTRUCTIVE PULMONARY-DISEASE | AFFINITY | IN-VIVO | DRUGS | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Benzamides - pharmacokinetics | Benzamides - blood | Humans | Aminopyridines - pharmacokinetics | Brain - enzymology | Cyclopropanes - blood | Macaca mulatta | Positron-Emission Tomography | Rolipram - blood | Aminopyridines - chemistry | Cyclopropanes - chemistry | Carbon Radioisotopes - chemistry | Animals | Aminopyridines - blood | Rolipram - pharmacokinetics | Aminopyridines - pharmacology | Female | Benzamides - pharmacology | Rolipram - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Rolipram - pharmacology | Benzamides - chemistry | Cyclopropanes - pharmacokinetics | Cyclopropanes - pharmacology | Binding | Brain | Animal models | Intravenous administration | Lung diseases | Cognitive ability | Positron emission | Phosphodiesterase IV | Inhibition (psychology) | Monkeys | Drug development | Studies | Rolipram | Inhibitors | Obstructive lung disease | Primates | Tomography | Emission measurements | Chronic obstructive pulmonary disease | Inhibition | Positron emission tomography | Phosphodiesterase
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 01/2015, Volume 21, Issue 3, pp. 317 - 331
Journal Article
Journal Article
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 01/2015, Volume 746, pp. 138 - 147
Hypertension (HT) is a prevailing risk factor for cognitive impairment, the most common cause of vascular dementia; yet, no possible mechanism underlying the... 
Hypertension | Roflumilast N-oxide | Cognition | Rolipram | Roflumilast | N-oxide | OBJECT RECOGNITION MEMORY | SILENT BRAIN INFARCTS | COGNITIVE IMPAIRMENT | BLOOD-PRESSURE | PDE4 INHIBITORS | WHITE-MATTER LESIONS | RENIN-ANGIOTENSIN SYSTEM | GENE-EXPRESSION | PHARMACOLOGY & PHARMACY | LONG-TERM POTENTIATION | PITUITARY-ADRENAL AXIS | Memory - drug effects | Gene Expression Regulation, Enzymologic - drug effects | Rats, Wistar | Benzamides - metabolism | Cyclopropanes - blood | Male | Aminopyridines - metabolism | RNA, Messenger - metabolism | Brain - physiology | Brain - metabolism | Cognition - physiology | Benzamides - pharmacology | Blood Pressure - drug effects | Corticosterone - blood | Rolipram - pharmacology | Cyclopropanes - pharmacology | Phosphodiesterase 4 Inhibitors - blood | Benzamides - blood | Brain - physiopathology | RNA, Messenger - genetics | Cyclopropanes - metabolism | Rats | Phosphodiesterase 4 Inhibitors - metabolism | Rolipram - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Cognition - drug effects | Maze Learning - drug effects | Phosphodiesterase 4 Inhibitors - pharmacology | Rolipram - blood | Hypertension - physiopathology | Brain - drug effects | Animals | Recognition (Psychology) - drug effects | Aminopyridines - blood | Aminopyridines - pharmacology | Clonidine | RNA | Gene expression | Protein binding | Index Medicus
Journal Article
Journal of Microbiology and Biotechnology, ISSN 1017-7825, 2017, Volume 27, Issue 2, p. 372
The transport of lysosomal enzymes into the lysosomes depends on the phosphorylation of their chains and the binding of the phosphorylated residues to... 
Lysosomes | rolipram | phosphodiesterase 4C
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2012, Volume 7, Issue 9, p. e43634
The extent of damage following spinal cord injury (SCI) can be reduced by various neuroprotective regimens that include maintaining levels of cyclic adenosine... 
CAMP-SPECIFIC PHOSPHODIESTERASE | DIFFERENTIAL EXPRESSION | MULTIDISCIPLINARY SCIENCES | CONTUSION INJURY | IMPROVES FUNCTIONAL RECOVERY | INHIBITOR ROLIPRAM | OLFACTORY ENSHEATHING GLIA | AMP-SPECIFIC PHOSPHODIESTERASE | RAT-BRAIN | SCHWANN-CELLS | NEURONAL DAMAGE | Oligodendroglia - metabolism | Spinal Cord Injuries - drug therapy | Motor Activity - drug effects | Rolipram - administration & dosage | Neuroglia - drug effects | Spinal Cord Injuries - pathology | Neuroprotective Agents - pharmacology | Oligodendroglia - drug effects | Spinal Cord Injuries - enzymology | Time Factors | Phosphodiesterase 4 Inhibitors - administration & dosage | Female | Neurons - metabolism | Phosphorylation - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Neurons - drug effects | Neuroprotective Agents - administration & dosage | Rolipram - pharmacology | Cell Survival - drug effects | Phosphoric Diester Hydrolases - metabolism | Phagocytes - drug effects | Axons - drug effects | Axons - metabolism | Rats | Phosphodiesterase 4 Inhibitors - pharmacology | Animals | Neuroglia - metabolism | Cytokines - biosynthesis | Complications and side effects | Enzyme inhibitors | Physiological aspects | Dosage and administration | Spinal cord injuries | Genetic aspects | Research | Drug therapy | Phosphodiesterases | Neuroprotection | Oxidative stress | Phosphorylation | Neurosciences | Multiple sclerosis | Spinal cord | Traumatic brain injury | Phosphodiesterase IV | Nervous system | Spinal cord injury | Kinases | Neuroprotective agents | Blood-brain barrier | Rodents | Oligodendrocytes | Paralysis | Phosphodiesterase | Adenosine | Cell survival | Adenosine monophosphate | Ethanol | Preservation | Cytokines | Cyclic AMP | Trauma | Medicine | Axons | Injury prevention | Rolipram | Inhibitors | Interleukin 10 | Infiltration | Alzheimers disease | Chemokines | Monocyte chemoattractant protein 1
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 10/2017, Volume 25, Issue 20, pp. 5709 - 5717
Journal Article